LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Effectiveness and Safety of Intravenous Medications for the Management of Acute Disturbance (Agitation and Other Escalating Behaviors): A Systematic Review of Prospective Interventional Studies.

    Castro, Megan / Butler, Matt / Thompson, Alysha Naomi / Gee, Siobhan / Posporelis, Sotiris

    Journal of the Academy of Consultation-Liaison Psychiatry

    2024  

    Abstract: Acute disturbance is a broad term referring to escalating behaviors secondary to a change in mental state, such as agitation, aggression, and violence. Available management options include de-escalation techniques and rapid tranquilization, mostly via ... ...

    Abstract Acute disturbance is a broad term referring to escalating behaviors secondary to a change in mental state, such as agitation, aggression, and violence. Available management options include de-escalation techniques and rapid tranquilization, mostly via parenteral formulations of medication. While the intramuscular route has been extensively studied in a range of clinical settings, the same cannot be said for intravenous (IV); this is despite potential benefits, including rapid absorption and complete bioavailability. This systematic review analyzed existing evidence for effectiveness and safety of IV medication for management of acute disturbances. It followed a preregistered protocol (PROSPERO identification CRD42020216456) and is reported following the guidelines set by Preferred Reporting Items for Systematic Review and Meta-Analysis. APA PsycINFO, MEDLINE, and EMBASE databases were searched for eligible interventional studies up until May 30th, 2023. Data analysis was limited to narrative synthesis since primary outcome measures varied significantly. Results showed mixed but positive results for the effectiveness of IV dexmedetomidine, lorazepam, droperidol, and olanzapine. Evidence was more limited for IV haloperidol, ketamine, midazolam, chlorpromazine, and valproate. There was no eligible data on the use of IV clonazepam, clonidine, diazepam, diphenhydramine, propranolol, ziprasidone, fluphenazine, carbamazepine, or promethazine. Most studies reported favorable adverse event profiles, though they are unlikely to have been sufficiently powered to pick up rare serious events. In most cases, evidence was of low or mixed quality, accentuating the need for further standardized, large-scale, multi-arm randomized controlled trials with homogeneous outcome measures. Overall, this review suggests that IV medications may offer an effective alternative parenteral route of administration in acute disturbance, particularly in general hospital settings.
    Language English
    Publishing date 2024-02-02
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 2667-2960
    ISSN (online) 2667-2960
    DOI 10.1016/j.jaclp.2024.01.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Managing patients with comorbidities: future models of care.

    Rayman, Gerry / Akpan, Asangaedem / Cowie, Martin / Evans, Rachael / Patel, Martyn / Posporelis, Sotiris / Walsh, Kieran

    Future healthcare journal

    2022  Volume 9, Issue 2, Page(s) 101–105

    Abstract: One in four adults in the UK have two or more medical conditions. One in three adults admitted to hospital in the UK have five or more conditions. People with multimorbidity have poorer functional status, quality of life and health outcomes, and are ... ...

    Abstract One in four adults in the UK have two or more medical conditions. One in three adults admitted to hospital in the UK have five or more conditions. People with multimorbidity have poorer functional status, quality of life and health outcomes, and are higher users of ambulatory and inpatient care than those without multimorbidity. The entire healthcare system needs to change so that it can provide a better service for patients with multimorbidity. The system of healthcare professional education needs to change also. Clinical decision support has a clear role in the management of patients with multimorbidity. But, until now, clinical decision support tools have offered no support when dealing with patients with comorbidities; they have covered single conditions only. In light of this, BMJ Best Practice recently launched the Comorbidities Manager. This enables healthcare professionals to add a patient's comorbidities to an existing management plan and get a tailored plan instantly. This article outlines the importance of taking into account comorbidities when managing patients and the role that the BMJ Comorbidities Manager can play in this regard.
    Language English
    Publishing date 2022-08-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 3016427-8
    ISSN 2514-6653 ; 2514-6645
    ISSN (online) 2514-6653
    ISSN 2514-6645
    DOI 10.7861/fhj.2022-0029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Suicidal and self-injurious behavior following adalimumab reference-to-generic biosimilar switch.

    Ward, Catherine / Farag, Mena / Pollak, Thomas A / Coutinho, Ester / Posporelis, Sotiris

    Psychiatry and clinical neurosciences

    2021  Volume 76, Issue 2, Page(s) 59–62

    MeSH term(s) Adalimumab ; Adult ; Biosimilar Pharmaceuticals ; Drug Substitution ; Drugs, Generic ; Humans ; Male ; Self-Injurious Behavior ; Suicidal Ideation
    Chemical Substances Biosimilar Pharmaceuticals ; Drugs, Generic ; Adalimumab (FYS6T7F842)
    Language English
    Publishing date 2021-12-07
    Publishing country Australia
    Document type Case Reports ; Letter
    ZDB-ID 1292906-2
    ISSN 1440-1819 ; 1323-1316
    ISSN (online) 1440-1819
    ISSN 1323-1316
    DOI 10.1111/pcn.13315
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Inflammatory and blood gas markers of COVID-19 delirium compared to non-COVID-19 delirium: a cross-sectional study.

    Saini, Aman / Oh, Tae Hyun / Ghanem, Dory Anthony / Castro, Megan / Butler, Matthew / Sin Fai Lam, Chun Chiang / Posporelis, Sotiris / Lewis, Glyn / David, Anthony S / Rogers, Jonathan P

    Aging & mental health

    2021  Volume 26, Issue 10, Page(s) 2054–2061

    Abstract: Objectives: We aimed to find the association of inflammation and respiratory failure with delirium in COVID-19 patients. We compare the inflammatory and arterial blood gas markers between patients with COVID-19 delirium and delirium in other medical ... ...

    Abstract Objectives: We aimed to find the association of inflammation and respiratory failure with delirium in COVID-19 patients. We compare the inflammatory and arterial blood gas markers between patients with COVID-19 delirium and delirium in other medical disorders.
    Methods: This cross-sectional study used the CHART-DEL, a validated research tool, to screen patients for delirium retrospectively from clinical notes. Inflammatory markers C-reactive protein (CRP) and white cell count (WBC), and the partial pressures of oxygen (PO
    Results: In bivariate analysis, CRP (mg/L) was significantly higher in the COVID-19 group, (81.7 ± 80.0 vs. 58.8 ± 87.7,
    Conclusion: The association between higher CRP and COVID-19 in patients with delirium may suggest an inflammatory basis for delirium in COVID-19. Our findings may assist clinicians in establishing whether delirium is due to COVID-19, which may improve management and outcomes of infected patients.
    MeSH term(s) Biomarkers ; C-Reactive Protein/analysis ; COVID-19 ; Cross-Sectional Studies ; Delirium/diagnosis ; Humans ; Retrospective Studies
    Chemical Substances Biomarkers ; C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2021-10-15
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1474804-6
    ISSN 1364-6915 ; 1360-7863
    ISSN (online) 1364-6915
    ISSN 1360-7863
    DOI 10.1080/13607863.2021.1989375
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation.

    Patel, Maxine X / Sethi, Faisil N / Barnes, Thomas Re / Dix, Roland / Dratcu, Luiz / Fox, Bernard / Garriga, Marina / Haste, Julie C / Kahl, Kai G / Lingford-Hughes, Anne / McAllister-Williams, Hamish / O'Brien, Aileen / Parker, Caroline / Paterson, Brodie / Paton, Carol / Posporelis, Sotiris / Taylor, David M / Vieta, Eduard / Völlm, Birgit /
    Wilson-Jones, Charlotte / Woods, Laura

    Journal of psychopharmacology (Oxford, England)

    2018  Volume 32, Issue 6, Page(s) 601–640

    Abstract: The British Association for Psychopharmacology and the National Association of Psychiatric Intensive Care and Low Secure Units developed this joint evidence-based consensus guideline for the clinical management of acute disturbance. It includes ... ...

    Abstract The British Association for Psychopharmacology and the National Association of Psychiatric Intensive Care and Low Secure Units developed this joint evidence-based consensus guideline for the clinical management of acute disturbance. It includes recommendations for clinical practice and an algorithm to guide treatment by healthcare professionals with various options outlined according to their route of administration and category of evidence. Fundamental overarching principles are included and highlight the importance of treating the underlying disorder. There is a focus on three key interventions: de-escalation, pharmacological interventions pre-rapid tranquillisation and rapid tranquillisation (intramuscular and intravenous). Most of the evidence reviewed relates to emergency psychiatric care or acute psychiatric adult inpatient care, although we also sought evidence relevant to other common clinical settings including the general acute hospital and forensic psychiatry. We conclude that the variety of options available for the management of acute disturbance goes beyond the standard choices of lorazepam, haloperidol and promethazine and includes oral-inhaled loxapine, buccal midazolam, as well as a number of oral antipsychotics in addition to parenteral options of intramuscular aripiprazole, intramuscular droperidol and intramuscular olanzapine. Intravenous options, for settings where resuscitation equipment and trained staff are available to manage medical emergencies, are also included.
    MeSH term(s) Acute Disease ; Aggression/drug effects ; Anti-Anxiety Agents/administration & dosage ; Antipsychotic Agents/administration & dosage ; Humans ; Mental Disorders/drug therapy ; Psychomotor Agitation/drug therapy ; Time Factors ; Violence/prevention & control
    Chemical Substances Anti-Anxiety Agents ; Antipsychotic Agents
    Language English
    Publishing date 2018-06-08
    Publishing country United States
    Document type Journal Article ; Practice Guideline ; Research Support, Non-U.S. Gov't
    ZDB-ID 639313-5
    ISSN 1461-7285 ; 0269-8811
    ISSN (online) 1461-7285
    ISSN 0269-8811
    DOI 10.1177/0269881118776738
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance

    Patel, Maxine X. / Sethi, Faisil N. / Barnes, Thomas R. E. / Dix, Roland / Dratcu, Luiz / Fox, Bernard / Garriga, Marina / Haste, Julie C. / Kahl, Kai G. / Lingford-Hughes, Anne / McAllister-Williams, Hamish / O'Brien, Aileen / Parker, Caroline / Paterson, Brodie / Paton, Carol / Posporelis, Sotiris / Taylor, David M. / Vieta, Eduard / Völlm, Birgit /
    Wilson-Jones, Charlotte / Woods, Laura

    Journal of Psychopharmacology

    De-escalation and rapid tranquillisation

    2018  Volume 32, Issue 6, Page(s) 601–640

    Abstract: The British Association for Psychopharmacology and the National Association of Psychiatric Intensive Care and Low Secure Units developed this joint evidence-based consensus guideline for the clinical management of acute disturbance. It includes ... ...

    Title translation Gemeinsame evidenzbasierte BAP NAPICU Konsensusrichtlinien für das klinische Management akuter Störungen: Deeskalation und schnelle Beruhigung (DeepL)
    Abstract The British Association for Psychopharmacology and the National Association of Psychiatric Intensive Care and Low Secure Units developed this joint evidence-based consensus guideline for the clinical management of acute disturbance. It includes recommendations for clinical practice and an algorithm to guide treatment by healthcare professionals with various options outlined according to their route of administration and category of evidence. Fundamental overarching principles are included and highlight the importance of treating the underlying disorder. There is a focus on three key interventions: de-escalation, pharmacological interventions pre-rapid tranquillisation and rapid tranquillisation (intramuscular and intravenous). Most of the evidence reviewed relates to emergency psychiatric care or acute psychiatric adult inpatient care, although we also sought evidence relevant to other common clinical settings including the general acute hospital and forensic psychiatry. We conclude that the variety of options available for the management of acute disturbance goes beyond the standard choices of lorazepam, haloperidol and promethazine and includes oral-inhaled loxapine, buccal midazolam, as well as a number of oral antipsychotics in addition to parenteral options of intramuscular aripiprazole, intramuscular droperidol and intramuscular olanzapine. Intravenous options, for settings where resuscitation equipment and trained staff are available to manage medical emergencies, are also included.
    Keywords Behandlungsleitlinien ; Drogen und Arzneimittel ; Drug Therapy ; Drugs ; Evidence Based Practice ; Evidenzbasierte Praxis ; Medikamentöse Therapie ; Psychiatrie ; Psychiatry ; Treatment Guidelines
    Language English
    Document type Article
    ZDB-ID 639313-5
    ISSN 0269-8811
    ISSN 0269-8811
    DOI 10.1177/0269881118776738
    Database PSYNDEX

    More links

    Kategorien

To top